EGEGazette
Live
Houthis Accuse Saudi Arabia of 28 Airstrikes in 24 Hours; U.S. Intelligence Chief Visits CairoWashington Warns Citizens of Unexpected Escalation in Middle EastIran Says Strait of Hormuz Will Stay Closed Until US Meets Its ConditionsTrump faces dual setback as U.S. courts block voting and immigration restrictionsLawsuit Filed Against Trump and His Company Over Paid Early Access Service to His PostsTrump Renews Bid to Restrict Birthright Citizenship Through Curbing "Birth Tourism"Trump Cuts Camp David Vacation Short Amid Middle East Escalation WarningsTrump Cuts Short Vacation, Returns to White House as US Issues "Possible Escalation" Warning in Middle EastReporters From CNN, MS NOW and Politico Denied White House Access After Trump BanFederal Immigration Agent Shoots and Injures Man in Austin, TexasPowerful Explosions Reported in Syria's Aleppo CountrysideSix Pakistani soldiers, including two officers, killed in clash near Afghan border
businessReported

Berenberg Upgrades Eli Lilly Stock, Citing Room for Growth in GLP-1 Market

The investment bank raised its rating on the pharmaceutical company to "buy" from "hold," pointing to continued momentum in weight-loss and diabetes drugs.

· 1 min read · language: en

Investment bank Berenberg has upgraded its rating on Eli Lilly, the maker of the diabetes and weight-loss drug Mounjaro, to "buy" from "hold," according to a report by CNBC.

The upgrade reflects Berenberg's view that the pharmaceutical company has additional room to grow amid the broader boom in GLP-1 medications, a class of drugs that includes treatments for diabetes and obesity, CNBC reported, citing the firm's analysis.

GLP-1 drugs, which mimic a hormone that regulates blood sugar and appetite, have seen surging demand in recent years as pharmaceutical companies race to meet growing consumer interest in weight-loss treatments. Eli Lilly's Mounjaro, along with its related drug Zepbound, has been among the products at the center of this expansion.

Details of Berenberg's specific price target or the rationale behind the rating change beyond the GLP-1 market outlook were not immediately available in the source material.

Eli Lilly has positioned itself as a major competitor in the GLP-1 drug space alongside other pharmaceutical companies developing similar treatments, as the market for these medications continues to expand globally.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Related articles

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…